G1 Therapeutics Inc (NASDAQ:GTHX) has been given a consensus recommendation of “Buy” by the eight analysts that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $74.00.
Several research analysts have recently weighed in on GTHX shares. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 8th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research note on Thursday, August 9th. JPMorgan Chase & Co. increased their price target on G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, August 10th. BTIG Research started coverage on G1 Therapeutics in a research note on Monday, September 10th. They set a “buy” rating and a $80.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $79.00 price target on shares of G1 Therapeutics in a research note on Monday, September 17th.
GTHX stock opened at $35.48 on Tuesday. The firm has a market cap of $1.42 billion, a PE ratio of -9.94 and a beta of 1.09. G1 Therapeutics has a fifty-two week low of $18.03 and a fifty-two week high of $69.57.
In related news, VP Jennifer K. Moses sold 750 shares of the stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $59.60, for a total transaction of $44,700.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Terry L. Murdock sold 3,523 shares of the stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $38.54, for a total value of $135,776.42. The disclosure for this sale can be found here. Insiders have sold a total of 50,363 shares of company stock worth $2,283,474 in the last three months. 15.92% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Pacer Advisors Inc. purchased a new stake in G1 Therapeutics during the 3rd quarter worth about $111,000. Great West Life Assurance Co. Can lifted its holdings in G1 Therapeutics by 148.3% during the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock worth $113,000 after purchasing an additional 1,560 shares in the last quarter. Strs Ohio lifted its holdings in G1 Therapeutics by 78.3% during the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock worth $178,000 after purchasing an additional 1,800 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in G1 Therapeutics during the 3rd quarter worth about $218,000. Finally, Citadel Advisors LLC purchased a new stake in G1 Therapeutics during the 3rd quarter worth about $243,000. 71.02% of the stock is currently owned by institutional investors and hedge funds.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Read More: Diversification
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.